Report overview
The biological product manufacturing is a complex process which produces products derived from recombinant DNA technology to develop a series of processes to manufacture therapeutic products. A biological product can be a virus, antitoxin, vaccine, blood component or derivative, allergenic product, or analogous product, or any therapeutic serum used for the treatment of a disease in humans. These biological products were developed from multicellular systems comprising of plants, animals, unicellular organisms and a mammalian cell. Biological products are composed of sugars, nucleic acids or combination of both.
This report aims to provide a comprehensive presentation of the global market for Biological Product Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biological Product Manufacturing. This report contains market size and forecasts of Biological Product Manufacturing in global, including the following market information:
Global Biological Product Manufacturing Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Biological Product Manufacturing market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The biological products are produced in three ways: by developing ways to achieve commercial production of the substance to be used, by gene alteration of the molecule and finally by developing an entirely new substance. Some of the tools used by modern day researcher in the manufacturing of biological products are recombinant DNA and monoclonal antibodies. Recombinant DNA involves altering of the DNA chain of one organism with desired DNA molecule to produce a novel biological product. Monoclonal antibodies were developed from single cell cultures using cloning techniques; these were designed to fight against toxins, viruses, and cancer cells. The first genetically engineered biological product approved for use in the U.S. was a vaccine for hepatitis-B which was approved in 1986, in the same year, other biological products like therapeutic monoclonal antibodies (MAB?s) and alpha interferon?s were approved.
We surveyed the Biological Product Manufacturing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biological Product Manufacturing Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Biological Product Manufacturing Market Segment Percentages, by Type, 2022 (%)
Monoclonal Antibodies
Recombinant Proteins
Growth Hormones
Beta Interferon
Therapeutic Enzymes
Global Biological Product Manufacturing Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Biological Product Manufacturing Market Segment Percentages, by Application, 2022 (%)
Hospitals
Specialized Clinics
Government Research Institutes
Global Biological Product Manufacturing Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Biological Product Manufacturing Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biological Product Manufacturing revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Biological Product Manufacturing revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
F.Hoffmann-La Roche
Merck
Bayer
Lonza
China Biologic Products
Pfizer
Sanofi
Teva Pharmaceutical Industries
Amgen
Outline of Major Chapters:
Chapter 1: Introduces the definition of Biological Product Manufacturing, market overview.
Chapter 2: Global Biological Product Manufacturing market size in revenue.
Chapter 3: Detailed analysis of Biological Product Manufacturing company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biological Product Manufacturing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
